Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 consensus report

…, F Di Mario, B Dragosics, M Farkkila… - Alimentary …, 2002 - kclpure.kcl.ac.uk
Significant progress and new insights have been gained in the 4 years since the first Maastricht
Consensus Report, necessitating an update of the original guidelines. To achieve this, …

Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory …

…, L de Ridder, I Dotan, M Färkkilä… - Journal of Crohn's …, 2011 - academic.oup.com
The healing of the intestine is becoming an important objective in the management of
inflammatory bowel diseases. It is associated with improved disease outcome. Therefore the …

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double …

…, N Witting, AM Autzen, J Pedersen, M Färkkilä… - The Lancet …, 2017 - thelancet.com
Background Complement is likely to have a role in refractory generalised myasthenia gravis,
but no approved therapies specifically target this system. Results from a phase 2 study …

Genome-wide meta-analysis identifies new susceptibility loci for migraine

…, DA Lawlor, DM Evans, SM Ring, M Färkkilä… - Nature …, 2013 - nature.com
Migraine is the most common brain disorder, affecting approximately 14% of the adult
population, but its molecular mechanisms are poorly understood. We report the results of a meta-…

Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings

…, H Nuutinen, U Turunen, M Färkkilä - Inflammatory bowel …, 2008 - academic.oup.com
Background Correlation of endoscopic Crohn's disease activity with fecal calprotectin and
lactoferrin is insufficiently studied. We evaluated the clinical significance of these neutrofil-…

Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

…, G Esmat, C Estes, S Ezzat, MA Färkkilä… - The Lancet …, 2022 - thelancet.com
Background Since the release of the first global hepatitis elimination targets in 2016, and until
the COVID-19 pandemic started in early 2020, many countries and territories were making …

A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis

…, I Elovaara, ML Sumelahti, M Färkkilä… - Journal of Neurology …, 2012 - jnnp.bmj.com
Objectives To study the safety and efficacy of vitamin D3 as an add on therapy to interferon β-1b
(IFNB) in patients with multiple sclerosis (MS). Methods 1 year, double blind, placebo …

Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora

…, A Kahri, M Saxelin, M Farkkila - Alimentary …, 2003 - Wiley Online Library
Background : Preliminary trials of probiotics in preventing recurrent chronic pouchitis have
been encouraging. Aim : To investigate the efficacy of Lactobacillus GG supplementation as …

[HTML][HTML] Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles

…, I de Boer, M Dichgans, C Erikstrup, M Färkkilä… - Nature …, 2022 - nature.com
Migraine affects over a billion individuals worldwide but its genetic underpinning remains
largely unknown. Here, we performed a genome-wide association study of 102,084 migraine …

Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure

K Kaukinen, L Halme, P Collin, M Färkkilä, M Mäki… - Gastroenterology, 2002 - Elsevier
BACKGROUND & AIMS:: Mild liver abnormalities are common in patients with celiac
disease and usually resolve with a gluten-free diet. We investigated the occurrence of celiac …